MiR-216a alleviates LPS-induced acute lung injury via regulating JAK2/STAT3 and NF-κB signaling

Area of Science:

• Molecular Biology
• Immunology
• Pulmonology

Background:

• MicroRNAs (miRNAs) are critical regulators in disease pathogenesis.
• Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe inflammatory lung conditions with high mortality.
• The specific role of miR-216a in ALI/ARDS remains largely unexplored.

Purpose of the Study:

• To investigate the role and mechanism of miR-216a in the pathogenesis of ALI/ARDS.
• To determine the therapeutic potential of miR-216a in ALI/ARDS models.

Main Methods:

• Analysis of miR-216a and inflammatory cytokine levels (IL-1β, IL-6, TNF-α) in ARDS patients and LPS-induced ALI mouse models.
• In vitro studies using A549 cells treated with LPS.
• Overexpression of miR-216a in ALI mice and cell models.
• Luciferase reporter assays to identify miR-216a targets.
• Western blotting to assess signaling pathway activation (JAK2/STAT3, NF-κB).

Main Results:

• ARDS patients and LPS-treated models showed decreased miR-216a expression and elevated inflammatory markers.
• miR-216a negatively correlated with ARDS patient survival.
• Overexpression of miR-216a reduced inflammation, lung permeability, apoptosis, and autophagy in ALI models.
• JAK2 was identified as a direct target of miR-216a.
• miR-216a suppressed JAK2/STAT3 and NF-κB signaling pathways.

Conclusions:

• miR-216a acts as a protective factor against LPS-induced inflammatory lung injury.
• Restoring miR-216a levels can ameliorate ALI/ARDS by inhibiting inflammation and regulating the JAK2/STAT3 and NF-κB signaling pathways.
• miR-216a represents a potential therapeutic target for ALI/ARDS.